CN102647981B - 预防和治疗脑缺血的方法 - Google Patents

预防和治疗脑缺血的方法 Download PDF

Info

Publication number
CN102647981B
CN102647981B CN201080048363.2A CN201080048363A CN102647981B CN 102647981 B CN102647981 B CN 102647981B CN 201080048363 A CN201080048363 A CN 201080048363A CN 102647981 B CN102647981 B CN 102647981B
Authority
CN
China
Prior art keywords
tocotrienol quinone
alpha
cerebral
subject
cerebral ischemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080048363.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102647981A (zh
Inventor
G.M.米勒
V.基菲特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Electronics Technology
Original Assignee
Edison Phamaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edison Phamaceuticals Inc filed Critical Edison Phamaceuticals Inc
Publication of CN102647981A publication Critical patent/CN102647981A/zh
Application granted granted Critical
Publication of CN102647981B publication Critical patent/CN102647981B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201080048363.2A 2009-08-26 2010-08-24 预防和治疗脑缺血的方法 Expired - Fee Related CN102647981B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27526909P 2009-08-26 2009-08-26
US61/275,269 2009-08-26
PCT/US2010/046503 WO2011025785A1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia

Publications (2)

Publication Number Publication Date
CN102647981A CN102647981A (zh) 2012-08-22
CN102647981B true CN102647981B (zh) 2016-09-28

Family

ID=42983642

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080048363.2A Expired - Fee Related CN102647981B (zh) 2009-08-26 2010-08-24 预防和治疗脑缺血的方法

Country Status (17)

Country Link
US (3) US20110207828A1 (enExample)
EP (1) EP2470168B1 (enExample)
JP (2) JP5785546B2 (enExample)
CN (1) CN102647981B (enExample)
AU (1) AU2010286704B2 (enExample)
BR (1) BR112012004167A2 (enExample)
CA (1) CA2772294C (enExample)
DK (1) DK2470168T3 (enExample)
EA (1) EA028677B1 (enExample)
ES (1) ES2663709T3 (enExample)
HU (1) HUE037592T2 (enExample)
MX (1) MX337990B (enExample)
NO (1) NO2470168T3 (enExample)
PL (1) PL2470168T3 (enExample)
PT (1) PT2470168T (enExample)
SI (1) SI2470168T1 (enExample)
WO (1) WO2011025785A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583087C (en) 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
CA2717734A1 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP3827815B1 (en) 2008-09-10 2023-09-06 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2010045220A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
TR201819154T4 (tr) 2008-10-28 2019-01-21 Bioelectron Tech Corp Alfa-tokotrienol kuinone ve ara ürünlerini içeren bileşim.
WO2010126911A1 (en) 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
EP2519232A1 (en) * 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
AU2011245384C1 (en) * 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
LT2680873T (lt) 2011-03-03 2017-11-27 Cidara Therapeutics, Inc. Priešgrybeliniai agentai ir jų panaudojimas
US9464016B2 (en) 2011-06-14 2016-10-11 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
GB201117808D0 (en) * 2011-10-14 2011-11-30 Siemens Medical Solutions SUV correction following dose infiltration
KR102236462B1 (ko) * 2012-03-19 2021-04-08 시다라 세라퓨틱스, 인코포레이티드 에키노칸딘 계열의 화합물에 대한 투여 용법
CA2883882A1 (en) * 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Benzoquinone derivatives for treating oxidative stress disorders
NZ628963A (en) * 2012-11-13 2017-02-24 Gordagen Pharmaceuticals Pty Ltd Transmucosal delivery of tocotrienol
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
RU2578451C1 (ru) * 2014-12-09 2016-03-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях
EP3233786B1 (en) 2014-12-16 2022-03-16 PTC Therapeutics, Inc. Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
EP3390377A1 (en) 2015-12-16 2018-10-24 BioElectron Technology Corporation Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
CA3017485A1 (en) 2016-03-16 2017-09-21 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
WO2019014333A1 (en) 2017-07-12 2019-01-17 Cidara Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS
WO2020010180A1 (en) * 2018-07-03 2020-01-09 Cardio Vascular Bio Therapeutics, Inc. Compositions and methods for treating stroke
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
PL3866772T3 (pl) 2018-10-17 2024-04-08 Ptc Therapeutics, Inc. 2,3,5-trimetylo-6-nonylocykloheksa-2,5-dieno-1,4-dion do hamowania i leczenia alfa-synukleinopatii, tauopatii i innych zaburzeń
KR20220078644A (ko) 2019-10-04 2022-06-10 스텔스 바이오테라퓨틱스 인코포레이티드 미토콘드리아 질환 치료를 위한 바티퀴논의 퀴논-, 히드로퀴논- 및 나프토퀴논-유사체
US20210162003A1 (en) * 2019-10-17 2021-06-03 The Penn State Research Foundation Regenerating functional neurons for treatment of hemorrhagic stroke
JP2023520462A (ja) 2020-04-03 2023-05-17 ステルス バイオセラピューティクス インコーポレイテッド フリードライヒ運動失調症を含むミトコンドリア病の予防および／または治療のための組成物および方法
EP4268183B1 (en) * 2020-12-22 2025-08-27 Koninklijke Philips N.V. Locating vascular constrictions
CN113066113B (zh) * 2021-04-27 2022-01-11 河北医科大学第二医院 自发性高血压大鼠脑模板和地图集的构建方法及设备
KR20240032997A (ko) 2021-07-08 2024-03-12 피티씨 테라퓨틱스, 인크. 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1441793A (zh) * 2000-07-14 2003-09-10 巴斯福股份公司 具有抗高胆固醇作用的生育三烯酚醌环化产物

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US6232060B1 (en) * 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
AU746369B2 (en) 1997-11-17 2002-04-18 Lipogenics, Inc. Methods for preventing restenosis using tocotrienols
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
AU2002239748A1 (en) * 2000-12-15 2002-06-24 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
MXPA04001555A (es) * 2001-08-21 2004-10-27 Galileo Pharmaceuticals Inc Composiciones enriquecidas con tocoferol y mejoramiento de sintomas inflamatorios.
WO2003043570A2 (en) * 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20040152764A1 (en) * 2001-12-14 2004-08-05 Miller Guy M. Compositions and methods for the prevention and treatment of cerebral ischemia
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
CA2583087C (en) * 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
PT1933821T (pt) * 2005-09-15 2020-10-15 Ptc Therapeutics Inc Variantes de cauda de terapêuticos redox-ativos para tratamento de doenças mitocondriais e outras condições e modulação de biomarcadores energéticos
JP5374162B2 (ja) * 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
CA2674368A1 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
EP3456707B1 (en) * 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
AU2008346956A1 (en) * 2008-01-07 2009-07-16 Centocor, Ortho Biotech Inc. Method of treating erythropoietin hyporesponsive anemias
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
CA2717734A1 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
WO2009111543A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
US20110142834A1 (en) * 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
EP2303309A2 (en) * 2008-05-22 2011-04-06 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
WO2010005989A1 (en) * 2008-07-09 2010-01-14 Edison Pharmaceuticals, Inc. Dermatological compositions with anti-aging and skin even-toning properties
WO2010014361A1 (en) * 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties
EP3827815B1 (en) * 2008-09-10 2023-09-06 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2010045220A1 (en) * 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
TR201819154T4 (tr) * 2008-10-28 2019-01-21 Bioelectron Tech Corp Alfa-tokotrienol kuinone ve ara ürünlerini içeren bileşim.
WO2010126909A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Formulation of tocotrienol quinones for the treatment of ophthalmic diseases
BRPI1015006A2 (pt) * 2009-04-28 2019-09-24 Ampere Life Sciences Inc uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas
WO2010126911A1 (en) * 2009-04-28 2010-11-04 Edison Pharmaceuticals, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
JP2012531411A (ja) * 2009-06-25 2012-12-10 アンペア ライフ サイエンシーズ，インコーポレイテッド トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置
EP2519232A1 (en) * 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
JP2013523816A (ja) * 2010-04-06 2013-06-17 エジソン ファーマシューティカルズ， インコーポレイテッド 毛細血管拡張性運動失調症の治療
AU2011245384C1 (en) * 2010-04-27 2016-09-01 Bioelectron Technology Corporation Formulations of quinones for the treatment of ophthalmic diseases
US20120101169A1 (en) * 2010-07-14 2012-04-26 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
US20120295985A1 (en) * 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1441793A (zh) * 2000-07-14 2003-09-10 巴斯福股份公司 具有抗高胆固醇作用的生育三烯酚醌环化产物

Also Published As

Publication number Publication date
EA201200355A1 (ru) 2012-07-30
US20180344667A1 (en) 2018-12-06
EA028677B1 (ru) 2017-12-29
PT2470168T (pt) 2018-03-28
EP2470168A1 (en) 2012-07-04
HUE037592T2 (hu) 2018-09-28
BR112012004167A2 (pt) 2016-03-29
NO2470168T3 (enExample) 2018-06-30
MX337990B (es) 2016-03-30
JP2013503168A (ja) 2013-01-31
SI2470168T1 (en) 2018-05-31
JP2015091899A (ja) 2015-05-14
MX2012002374A (es) 2012-04-10
EP2470168B1 (en) 2018-01-31
PL2470168T3 (pl) 2018-06-29
AU2010286704A1 (en) 2012-03-22
DK2470168T3 (en) 2018-05-07
CN102647981A (zh) 2012-08-22
CA2772294C (en) 2018-08-21
US20110207828A1 (en) 2011-08-25
JP5785546B2 (ja) 2015-09-30
WO2011025785A1 (en) 2011-03-03
ES2663709T3 (es) 2018-04-16
CA2772294A1 (en) 2011-03-03
US20170007553A1 (en) 2017-01-12
AU2010286704B2 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
CN102647981B (zh) 预防和治疗脑缺血的方法
US7034054B2 (en) Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
JP2017081930A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
US20100197610A1 (en) Fructose 1, 6 bisphosphate - a novel anticonvulsant drug
CA2982645C (en) Composition for suppressing muscular fatty change
CN105943530B (zh) 铁死亡抑制剂在制备治疗铁过载疾病的药物中的应用
Chen et al. Cebocephaly, alobar holoprosencephaly, spina bifida, and sirenomelia in a stillbirth.
CN115315197A (zh) 细胞衰老抑制用组合物及抑制细胞衰老的方法
HK1171665B (en) Methods for the prevention and treatment of cerebral ischemia
HK1171665A (en) Methods for the prevention and treatment of cerebral ischemia
US9029419B2 (en) Use of zinc N-acetyltaurinate
JP2021522283A (ja) 分子ピンセットによるリポフスチンの凝集の阻害
TWI736173B (zh) 牛樟芝菌絲體的液態培養萃取物、牛樟芝菌絲體的液態培養萃取物的化合物及其用於治療缺血性腦中風的用途
US20040152764A1 (en) Compositions and methods for the prevention and treatment of cerebral ischemia
CN112807296A (zh) 琥珀酸在诊断或治疗自然流产中的应用
CN116801866A (zh) α-细辛脑在制备预防或治疗出血性脑卒中药物中的应用
Sun et al. Kudiezi Injection Attenuates Apoptosis and Neuroinflammation for Ameliorating Angiogenesis via miR-21/PDCD4/NF-κB Axis in MCAO/Reperfusion Rats
CN115581702A (zh) 芍药素-3-o-阿拉伯糖苷在制备药物或保健食品的应用
JP2002121132A (ja) 発がん抑制剤および発がん抑制方法
CN115645430A (zh) 飞燕草素-3-o-半乳糖苷在制备药物或保健食品的应用
KR20200126354A (ko) 진세노사이드 Rb2를 포함하는 신경세포 보호용 조성물
WO2007097455A1 (ja) パウ・フェロから単離された新規化合物
HK40082585A (en) Composition for suppressing cellular senescence, and method for suppressing cellular senescence
CN115721667A (zh) 三七总皂苷和乙酰天麻素在肌萎缩侧索硬化症中的应用
KR20200042745A (ko) 진세노사이드 Rb2를 포함하는 신경세포 보호용 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: American California

Patentee after: Bio Electronics Technology

Address before: American California

Patentee before: Edison Pharmaceuticals, Inc.

CP01 Change in the name or title of a patent holder
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160928

Termination date: 20190824

CF01 Termination of patent right due to non-payment of annual fee